ContraFect to Present at the 29th Annual Piper Jaffray Healthcare Conference
November 15 2017 - 7:00AM
ContraFect Corporation (NASDAQ:CFRX), a biotechnology company
focused on the discovery and development of protein and antibody
therapeutics for life-threatening, drug-resistant infectious
diseases, announced today that Steven C. Gilman, PhD, the Company's
Chairman and CEO, will participate in an analyst-led fireside chat
at the 29th Annual Piper Jaffray Healthcare Conference on
Wednesday, November 29, 2017 at 2:00 PM ET in New York, NY. The
chat will feature a one-on-one conversation followed by an
interactive question and answer session. The focus will be on
ContraFect's lead program, CF-301, the Company's novel approach to
the treatment of drug-resistant Staphylococcus aureus (Staph
aureus) infections, including MRSA.
The presentation will be available as a webcast for a limited
time. To access via the Company's website, please go to
www.contrafect.com. To access the webcast directly, please use the
following URL:
https://event.webcasts.com/starthere.jsp?ei=1171743&tp_key=de4ad06327
About ContraFect:
ContraFect is a biotechnology company focused on discovering and
developing therapeutic protein and antibody products for
life-threatening, drug-resistant infectious diseases, particularly
those treated in hospital settings. An estimated 700,000 deaths
worldwide each year are attributed to antimicrobial-resistant
infections. We intend to address life threatening infections using
our therapeutic product candidates from our lysin and monoclonal
antibody platforms to target conserved regions of either bacteria
or viruses (regions that are not prone to mutation). ContraFect's
initial product candidates include new agents to treat
antibiotic-resistant infections such as MRSA (Methicillin-resistant
Staphylococcal aureus) and influenza. The Company’s lead lysin,
CF-301, is currently being studied in a Phase 2 multicenter,
multinational, randomized, controlled clinical trial in patients
with Staphylococcal aureus (Staph aureus) bacteremia including
endocarditis. ContraFect is also conducting research focused on the
discovery of lysins to target Gram-negative bacteria.
About CF-301: CF-301 is a recombinant
bacteriophage-derived lysin with potent bactericidal activity
against Staph aureus, a major cause of blood stream infections, or
bacteremia. CF-301 has the potential to be a first-in-class
treatment for Staph aureus bacteremia. It has a novel, rapid,
and specific mechanism of bactericidal action against Staph aureus
and does not impact the body's natural bacterial flora. By
targeting a conserved region of the cell wall that is vital to
bacteria, resistance is less likely to develop to CF-301.
Combinations of CF-301 with standard of care antibiotics
significantly increased bacterial killing and survival in animal
models of disease when compared to treatment with antibiotics or
CF-301 alone. In addition, in vitro and in vivo experiments have
shown that CF-301 is highly active against biofilm infections.
CF-301 was licensed from The Rockefeller University and is being
developed at ContraFect. It is the first lysin to enter clinical
studies in the U.S.
FORWARD-LOOKING STATEMENTS
This press release contains, and our officers and
representatives may make from time to time, “forward-looking
statements” within the meaning of the U.S. federal securities
laws. Forward-looking statements can be identified by words
such as “projects,” “may,” “will,” “could,” “would,” “should,”
“believes,” “expects,” “anticipates,” “estimates,” “intends,”
“plans,” “potential,” “promise” or similar references to future
periods. Examples of forward-looking statements in this release
include, without limitation, statements regarding our ability to
discover and develop protein and antibody therapeutics for
life-threatening, drug-resistant infectious diseases, our ability
to address life threatening infections using our therapeutic
product candidates from our lysin and monoclonal antibody platforms
to target conserved regions of either bacteria or viruses, whether
our initial product candidates can treat antibiotic-resistant
infections such as MRSA (Methicillin-resistant Staph aureus) and
influenza, and our ability to discover new lysins to target
Gram-negative bacteria,. Forward-looking statements are statements
that are not historical facts, nor assurances of future
performance. Instead, they are based on ContraFect’s current
beliefs, expectations and assumptions regarding the future of its
business, future plans, strategies, projections, anticipated events
and trends, the economy and other future conditions. Because
forward-looking statements relate to the future, they are subject
to inherent risks, uncertainties and changes in circumstances that
are difficult to predict and many of which are beyond ContraFect’s
control, including those detailed in ContraFect's filings with the
Securities and Exchange Commission. Actual results may differ
from those set forth in the forward-looking statements. Important
factors that could cause actual results to differ include, among
others, our ability to develop treatments for drug-resistant
infectious diseases. Any forward-looking statement made by
ContraFect in this press release is based only on information
currently available and speaks only as of the date on which it is
made. Except as required by applicable law, ContraFect expressly
disclaims any obligations to publicly update any forward-looking
statements, whether written or oral, that may be made from time to
time, whether as a result of new information, future developments
or otherwise.
Investor Relations Contact
Paul Boni
ContraFect Corporation
Tel: 914-207-2300
Email: pboni@contrafect.com
ContraFect (NASDAQ:CFRX)
Historical Stock Chart
From Aug 2024 to Sep 2024
ContraFect (NASDAQ:CFRX)
Historical Stock Chart
From Sep 2023 to Sep 2024